Drug Information

General Information
Drug ID
DR00145
Drug Name
Mercaptopurine
Synonyms
1,7-Dihydro-6H-purine-6-thione; 1,9-dihydro-6H-purine-6-thione; 3,7-dihydropurine-6-thione; 3H-Purine-6-thiol; 6 MP; 6 Mercaptopurine; 6 Mercaptopurine Monohydrate; 6 Thiohypoxanthine; 6 Thiopurine; 6-MERCAPTOPURINE MONOHYDRATE; 6-MP; 6-Mercaptopurin; 6-Mercaptopurine; 6-Merkaptopurin; 6-Merkaptopurin [Czech]; 6-Purinethiol; 6-Thiohypoxanthine; 6-Thiopurine; 6-Thioxopurine; 7-Mercapto-1,3,4,6-tetrazaindene; 7H-purine-6-thiol; 9H-Purin-6-yl hydrosulfide; 9H-Purine-6(1H)-thione; AG-670/31547064; BW 57 323H; Glaxo Wellcome Brand of 6 Mercaptopurine; Glaxo Wellcome Brand of 6-Mercaptopurine; GlaxoSmithKline Brand of 6 Mercaptopurine; GlaxoSmithKline Brand of 6-Mercaptopurine; Ismipur; Leukerin; Leukerin, 99%-Carc; Leupu rin; Leupurin; M0063; Mercaleukim; Mercaleukin; Mercaptopurin; Mercaptopurin [German]; Mercaptopurina; Mercaptopurina Wellcome; Mercaptopurina [INN-Spanish]; Mercaptopurine (INN); Mercaptopurine (Purine analog); Mercaptopurine (VAN); Mercaptopurine (anhydrous); Mercaptopurine anhydrous; Mercaptopurinum; Mercaptopurinum [INN-Latin]; Mercapurin; Merkaptopuryna; Merkaptopuryna [Polish]; Mern; NCIMech_000025; PM6; Puri Nethol; Puri-Nethol; Purimethol; Purine-6(1H)-thione; Purine-6-thiol; Purineantimetabolite: inhibits nucleic acid replication; Purinethiol; Purinethol; Purinethol (TN); Purinethol, 6-mercaptopurine, 6-MP, Mercaptopurine; Thiopurine; U-4748; Wellcome Brand of 6 Mercaptopurine; Wellcome Brand of 6-Mercaptopurine
Drug Type
Small molecular drug
Indication Acute lymphoblastic leukemia [ICD11: 2B33.0] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
3D MOL 2D MOL
Formula
C5H4N4S
Canonical SMILES
C1=NC2=C(N1)C(=S)N=CN2
InChI
InChI=1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)
InChIKey
GLVAUDGFNGKCSF-UHFFFAOYSA-N
CAS Number
CAS 50-44-2
Pharmaceutical Properties Molecular Weight 152.18 Topological Polar Surface Area 85.2
Heavy Atom Count 10 Rotatable Bond Count 0
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 2
XLogP
0
PubChem CID
667490
PubChem SID
11335668 , 11360907 , 11363815 , 11364775 , 11366377 , 11367337 , 11368939 , 11369899 , 11371581 , 11372939 , 11374631 , 11375499 , 11377101 , 11378064 , 11446005 , 11446674 , 11461879 , 11483955 , 11487876 , 11490307 , 11492672 , 11494735 , 14772317 , 15321640 , 15970891 , 16997018 , 24882910 , 25622685 , 26611807 , 26679290 , 26748122 , 26748123 , 26748124 , 31299583 , 31665082 , 3205553 , 4889 , 4912489 , 5334583 , 5370645 , 538245 , 5422 , 602747 , 6477910 , 7366114 , 7979906 , 8136889 , 8148223 , 8149413 , 9276666
ChEBI ID
ChEBI:50667
TTD Drug ID
D09UZO
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
CNT2 Transporter Info Concentrative nucleoside transporter 2 Substrate [3]
CNT3 Transporter Info Concentrative Na(+)-nucleoside cotransporter 3 Substrate [4]
ENBT1 Transporter Info Equilibrative nucleobase transporter 1 Substrate [5]
ENT1 Transporter Info Equilibrative nucleoside transporter 1 Substrate [3]
ENT2 Transporter Info Equilibrative nucleoside transporter 2 Substrate [3]
MRP4 Transporter Info Multidrug resistance-associated protein 4 Substrate [6]
MRP5 Transporter Info Multidrug resistance-associated protein 5 Substrate [7]
OAT3 Transporter Info Organic anion transporter 3 Substrate [8]
References
1 Mercaptopurine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol. 2012 Apr 15;83(8):1073-83.
3 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)
4 Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochem Biophys Res Commun. 2006 Apr 28;343(1):208-15.
5 Characterization of 6-Mercaptopurine Transport by the SLC43A3-Encoded Nucleobase Transporter. Mol Pharmacol. 2019 Jun;95(6):584-596.
6 Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009 Aug 13;114(7):1383-6.
7 Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine. Springerplus. 2014 Dec 13;3:732.
8 Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem. 2004 Aug;90(4):931-41.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.